Colchicine 0.5 mg Tablets

The 0.5 mg strength is the first decision point

Our listing is for Colchicine 0.5 mg oral tablets. The most important purchasing decision is not simply whether colchicine is the required active ingredient, but whether this exact strength and labeled product match the intended treatment. In the United States, FDA approval, indications, and dosing instructions attach to a specific finished medicine; they cannot be assumed from the word "colchicine" or from the strength alone.

This distinction is especially important because FDA-approved 0.5 mg colchicine is available under the brand name Lodoco for reducing cardiovascular events in certain adults with established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. Colchicine also has established roles in gout and familial Mediterranean fever, but a buyer should not assume that every 0.5 mg tablet carries all of those indications. Confirm the product label, intended use, and dosing instructions with a prescriber or pharmacist before choosing a package.

Product identity and clinical role

Each tablet in this listing contains 0.5 mg of colchicine and is taken by mouth. Colchicine is commonly classified as an antigout agent, although its anti-inflammatory effects are used in more than one clinical setting. It is not an NSAID, corticosteroid, pain reliever, or uric acid-lowering medicine.

For gout, colchicine may be prescribed to treat a flare or help prevent flares in an appropriate formulation and regimen. For familial Mediterranean fever, it may be used as continuing treatment to reduce inflammatory attacks and complications. Low-dose colchicine also has a separate cardiovascular role when supplied and prescribed as the specifically approved product. These uses involve different clinical goals, schedules, and labeling, so they should not be treated as interchangeable simply because the active ingredient is the same.

Our listing identifies the medicine as Colchicine rather than as Colcrys or Lodoco. A brand name, generic name, and active ingredient may overlap without establishing that two finished products have the same approved indications. Check the packaging and accompanying medicine information when the order is received, and ask our support team if the listing details need clarification before checkout.

Who should consider this product with a prescriber?

Colchicine is generally considered after a clinician has identified a specific reason for treatment. It is not a suitable way to self-diagnose new joint pain, unexplained swelling, recurrent fever, chest symptoms, or cardiovascular risk. Several conditions can resemble a gout flare, and the correct treatment depends on the diagnosis as well as the product label.

• Someone prescribed colchicine should confirm that the prescription or treatment plan specifies 0.5 mg tablets rather than another strength.
• A person considering it for gout should establish whether the goal is flare treatment, short-term prevention when another therapy is started, or longer-term prophylaxis.
• A person with familial Mediterranean fever needs a continuing regimen selected according to age, response, tolerability, and the applicable product instructions.
• A person considering low-dose colchicine for cardiovascular risk reduction should confirm that the prescribed product and indication correspond to the FDA-approved cardiovascular labeling.
• Anyone with kidney disease, liver disease, a history of blood disorders, neuromuscular symptoms, or several current medicines needs an interaction and dose review before treatment.

Colchicine has a relatively narrow safety margin. A dose that is appropriate for one indication or patient may not be appropriate for another, and taking extra tablets can cause serious or fatal toxicity. Product selection should therefore begin with the exact strength and labeled use rather than with package size or convenience.

How colchicine acts in the body

Colchicine alters microtubule activity inside cells and reduces several steps in the inflammatory response. In gout, this limits the response of white blood cells to urate crystals in a joint. It can reduce inflammation from a flare, but it does not remove urate crystals or lower the amount of uric acid in the blood.

That difference matters in long-term gout care. A person may be prescribed colchicine to prevent flares while also taking a separate urate-lowering medicine such as Allopurinol. The two medicines serve different purposes. Colchicine controls inflammatory activity, while urate-lowering treatment addresses the underlying uric acid level over time.

In familial Mediterranean fever, continuing colchicine treatment reduces inflammatory attacks and helps protect against complications. In its approved cardiovascular role, low-dose colchicine is intended to reduce inflammatory processes associated with cardiovascular events. It does not replace cholesterol management, blood pressure control, smoking cessation, antiplatelet treatment when indicated, or other measures selected by a clinician.

How should the tablets be used safely?

Use Colchicine 0.5 mg tablets only according to the directions for the specific product and indication. Gout flare treatment, gout prophylaxis, familial Mediterranean fever treatment, and cardiovascular risk reduction do not share one universal schedule. A dosing instruction for another strength or brand should not be converted without professional guidance.

1. Check that the prescribed strength is 0.5 mg and that the product label corresponds to the intended use.
2. Follow the exact number of tablets and dosing interval provided by the prescriber or product instructions.
3. Do not take additional tablets because symptoms remain uncomfortable or because a dose was missed. Obtain missed-dose advice from the applicable instructions or a healthcare professional.
4. Do not share colchicine with another person, even if that person reports similar symptoms.
5. Keep an up-to-date list of prescription medicines, nonprescription products, and supplements so that interactions can be checked.
6. Seek immediate advice after an accidental overdose or dosing error, even if symptoms have not yet appeared.

Store the tablets at 68°F to 77°F; brief excursions between 59°F and 86°F are permitted. Keep them in the original container and protect them from light and moisture. Store all medicines where children and other household members cannot take them accidentally.

Our available package quantities

We offer one strength, 0.5 mg, in packages of 60, 90, 120, 180, 270, or 360 tablets. These quantities provide a choice of supply size without changing the strength or dosage form. Selecting more tablets does not change how the medicine should be taken.

The appropriate quantity depends on the verified regimen and expected duration of treatment. A short course, an intermittent regimen, and continuing daily treatment can require very different amounts. Because the exact use cannot be inferred from the package quantity, calculate the required supply from the instructions provided for this product rather than from a general colchicine schedule found elsewhere.

Before choosing a larger package, consider whether the regimen is stable, whether follow-up or laboratory monitoring is planned, and whether any medicine changes could affect continued use. Also check the expiration and storage information after receiving the package. Ordering more than the planned treatment requires can lead to unnecessary medicine remaining in the home.

Expected results depend on the indication

There is no single response timeline for every use of colchicine. When an appropriate colchicine product is prescribed early for a gout flare, improvement may begin during the first day or two, although the flare can take longer to settle. Lack of immediate relief is not a reason to take extra tablets. Persistent or worsening symptoms require clinical review because the diagnosis, timing, interaction profile, or treatment choice may need reconsideration.

When colchicine is used to prevent gout flares or manage familial Mediterranean fever, success is assessed over time by changes in the frequency and severity of attacks and by tolerability. Preventive treatment may not produce a sensation that the medicine is working. Adherence to the selected regimen and planned follow-up are more useful than judging it after one dose.

Cardiovascular risk reduction is also a long-term preventive goal rather than an effect a person can feel. It should not be evaluated through day-to-day symptoms, and colchicine should not be used to respond to possible heart attack or stroke symptoms. Chest pressure, sudden weakness, facial drooping, difficulty speaking, or other emergency symptoms require immediate emergency care.

Safety priorities and warning signs

Gastrointestinal effects are common with colchicine, but they can also be early signs that exposure is too high. Diarrhea, nausea, vomiting, and abdominal pain should not automatically be dismissed, particularly when symptoms are severe, persistent, or accompanied by weakness or dehydration. Contact a healthcare professional for advice rather than changing the dose independently.

Prompt medical assessment is important for unusual bruising or bleeding, fever or other signs of infection, severe muscle pain or weakness, numbness or tingling, pale skin, marked fatigue, reduced urination, or persistent vomiting or diarrhea. These symptoms may indicate blood-cell, muscle, nerve, kidney, or systemic toxicity. An overdose can initially resemble a severe gastrointestinal illness and may later cause life-threatening organ damage.

People with a known allergy to colchicine or another product ingredient should not use the medicine. Pregnancy requires an individualized benefit-risk decision. Colchicine crosses the placenta, and the available human evidence must be considered alongside the reason treatment is needed, the dose, organ function, and interacting medicines. Colchicine is also present in human milk. Breastfeeding decisions should account for the mother's clinical need and observation of the infant for gastrointestinal effects such as diarrhea.

Pediatric use depends on the indication, age, dose, and labeled product. Colchicine has established use for familial Mediterranean fever in some children aged 4 years and older, but that does not make every tablet or indication suitable for a child. Pediatric dosing must be set by an appropriate clinician.

Interactions can determine whether colchicine is suitable

Colchicine is handled by the CYP3A4 enzyme and the P-glycoprotein transport system. Medicines that strongly inhibit either pathway can raise colchicine exposure and increase the risk of severe toxicity. This risk can become especially dangerous when kidney or liver function is impaired.

• Some macrolide antibiotics, particularly clarithromycin, can substantially increase colchicine levels.
• Certain azole antifungals, HIV medicines, transplant medicines, and other strong CYP3A4 or P-glycoprotein inhibitors may require avoidance or a carefully managed change in treatment.
• Verapamil, diltiazem, and some other cardiovascular medicines can affect colchicine exposure.
• Statins, fibrates, and other medicines associated with muscle injury may increase concern about muscle toxicity when used with colchicine.
• Grapefruit and grapefruit juice can affect CYP3A4 activity and should be discussed with a pharmacist or prescriber.

This is not a complete interaction list. Do not stop an antibiotic, cholesterol medicine, heart medicine, or other necessary treatment solely because it appears in a general list. A prescriber or pharmacist should assess the exact medicines, doses, duration, kidney and liver function, and reason colchicine is being used.

Reduced kidney or liver function may require dose adjustment, less frequent dosing, closer monitoring, or selection of another treatment. In some circumstances, combining colchicine with a strong interacting medicine is contraindicated. This review should happen before the first dose whenever possible, not only after side effects appear.

Which alternatives may be more appropriate?

The relevant comparison depends on why colchicine is being considered. Alternatives for an acute gout flare are not substitutes for long-term uric acid control, and neither group should be treated as an alternative to a specifically approved cardiovascular product.

• For an acute gout flare, an NSAID such as naproxen or indomethacin or a corticosteroid such as prednisone may be considered. Kidney function, ulcer or bleeding risk, cardiovascular conditions, diabetes, and other medicines influence that choice.
• For long-term gout management, urate-lowering medicines such as Allopurinol, febuxostat, or probenecid address uric acid rather than directly treating the inflammation of an active flare. Colchicine may be used temporarily alongside urate-lowering treatment to reduce flare risk.
• For familial Mediterranean fever, colchicine is a foundational treatment. Specialist-directed biologic therapy may be considered when there is confirmed resistance or intolerance, but it is not a routine interchangeable choice.
• For cardiovascular risk reduction, Lodoco is used as an adjunct in selected adults. It does not replace standard cardiovascular prevention, and another gout-labeled colchicine product should not be assumed to provide the same labeled option.

No medicine is universally preferable. The decision depends on the confirmed diagnosis, exact objective, product label, organ function, interaction profile, prior response, and ability to follow the regimen safely.

U.S. prescription status and our ordering policy

Colchicine is a prescription-only medicine in the United States. FDA-approved prescribing information for individual colchicine products is available through DailyMed and includes the applicable indications, doses, contraindications, interactions, and warnings. Suspected serious adverse events and product-quality concerns can be reported to the FDA MedWatch program.

The U.S. regulatory classification is separate from our ordering process. Our ordering policy for this listing does not require a prescription upload at checkout. That is a statement about what our checkout requests; it does not make colchicine an over-the-counter medicine or broaden the approved uses of any product.

A customer should still have an appropriate clinician confirm the reason for treatment, strength, regimen, and interaction profile. Our pharmacist can help with product and medicine questions, but support does not replace diagnosis, prescribing, emergency assessment, or individualized follow-up.

Ordering and receiving the correct product

Before placing an order, select one of the package quantities we offer and verify that the listing shows Colchicine 0.5 mg tablets. Check the strength carefully because colchicine products in the United States may use a different strength, and tablet counts alone do not establish equivalence.

Our support team is available 24/7 by email, online chat, or phone, and a pharmacist is available for medicine-related questions. Customers can contact us before checkout if they need clarification about the listed strength, dosage form, package quantity, or ordering process.

When the package arrives, compare the product name, 0.5 mg strength, tablet count, labeling, expiration information, and container condition with the order. Do not use the tablets if the strength or identity does not match the intended product, the seal or container appears compromised, or the labeling is unclear. Contact our support team so the order details can be reviewed.

A focused final decision

Colchicine 0.5 mg tablets are a reasonable product to consider only when the active ingredient, oral tablet form, exact strength, labeled indication, and planned regimen all match. The shared ingredient does not make every colchicine product interchangeable: gout treatment, gout prophylaxis, familial Mediterranean fever management, and cardiovascular risk reduction have different labeling and practical requirements.

Before choosing among our packages of 60 to 360 tablets, confirm the intended use and calculate the quantity from the verified regimen. Review kidney and liver function, current medicines, and important interaction risks with a prescriber or pharmacist. Knowing how to respond to gastrointestinal effects, muscle symptoms, blood-cell warning signs, and dosing errors is equally important because colchicine toxicity can be severe.

The strongest purchase decision is therefore based on product identity and clinical fit rather than on strength or package size in isolation. Once those points are confirmed, select the package quantity that corresponds to the planned course and use our support channels if any listing or order detail remains unclear.